7 citations
,
April 2021 in “Journal of advanced pharmaceutical technology & research” This study reported that compound 16 (olean-12-en-3beta-ol, cinnamate) from Merremia peltata showed potential as an androgen receptor antagonist, suggesting it may benefit alopecia treatment based on molecular docking and ADME-Tox predictions.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.
March 2026 in “Jurnal Pharmascience” This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.
January 2026 in “Chemistry & Biodiversity” This study found that the chemical composition and biological activity of Platycladus orientalis fruit extracts varied with the extraction method, revealing potent antioxidant and enzyme inhibitory properties, particularly in the n-hexane extract, which suggests potential applications for managing dysregulated enzyme conditions.